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Background. Single-dose albendazole and mebendazole show limited efficacy in the treatment of trichuriasis.
The combination of albendazole with ivermectin improves efficacy, but a mebendazole-ivermectin combination
has not been previously investigated.
Methods. We performed a randomized controlled trial in 2 schools in Zanzibar, Tanzania, to assess the efficacy
and safety of albendazole (400 mg) plus placebo, albendazole plus ivermectin (200 mg/kg), mebendazole (500 mg)
plus placebo, and mebendazole plus ivermectin in children with a parasitologically confirmed Trichuris trichiura
infection. Cure rate (CR) and egg reduction rate were assessed by intent-to-treat analysis. Adverse events were
monitored within 48 h after treatment.
Results. Complete data records were available for 548 children. The highest CR against T. trichiura was achieved
with a mebendazole-ivermectin combination (55%). Low CRs were observed with albendazole-ivermectin (38%),
mebendazole (19%), and albendazole (10%). Compared with placebo, the use of ivermectin statistically significantly
increased the CRs from 14% to 47% (odds ratio, 0.19; 95% confidence interval [CI], 0.12–0.28). The highest egg
reduction rate (97%; 95% CI, 95%–98%) was observed using the mebendazole-ivermectin combination, followed
by albendazole-ivermectin (91%; 95% CI, 87%–94%), mebendazole (67%; 95% CI, 52%–77%), and albendazole
(40%; 95% CI, 22%–56%). The adverse events, reported by 136 children, were generally mild, with no significant
difference between the treatment arms.
Conclusions. Addition of ivermectin improves the therapeutic outcomes of both albendazole and mebendazole
against T. trichiura and may be considered for use in soil-transmitted helminth control programs and individual
patient management.
Trial registration. isrctn.org Identifier: ISRCTN08336605.
An estimated 604 million to 795 million people are
infected with the whipworm Trichuris trichiura, causing
a global burden of 6.4 million disability-adjusted life-
years lost [1–3]. The current strategy against T. trichiura
and other soil-transmitted helminth infections (Ascaris
lumbricoides and hookworm) is to regularly adminis-
ter anthelmintic drugs, mainly albendazole and meben-
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dazole, to school-aged children and other at-risk pop-
ulations [4, 5]. Although both drugs show good ther-
apeutic profiles against A. lumbricoides, mebendazole
fails to effectively clear hookworm infections, and nei-
ther drug is satisfactory against T. trichiura. In a meta-
analysis of randomized, placebo-controlled trials, the
average cure rate (CR) of single-dose albendazole (400
mg) against T. trichiura was reported to be only 28%.
Mebendazole (500 mg), with an average CR of 36%,
performed slightly better [6]. Improved treatment out-
comes against T. trichiura were observed when using
triple-dose treatments of either drug [7]. Albendazole
and mebendazole can be coadministered with other
deworming drugs; foremost is the combination of al-
bendazole with ivermectin (200 or 400 mg/kg) as used
against lymphatic filariasis. This combination therapy
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showed promising results against T. trichiura; observed CRs
were 65% and 80% in 2 trials [8, 9]. However, a third trial
found no effect by adding ivermectin to albendazole [10]. De-
spite the somewhat higher efficacy of mebendazole compared
with albendazole against trichuriasis, the efficacy and safety of
a mebendazole-ivermectin combination have yet to be inves-
tigated [7, 11].
In Zanzibar, control programs have significantly reduced the
prevalence and intensity of soil-transmitted helminthiasis [12].
However, in contrast to A. lumbricoides and hookworm, the
prevalence of T. trichiura infections has remained high [12, 13].
Against this background, we were motivated to assess the ef-
ficacy and safety of albendazole and mebendazole combined
with ivermectin against T. trichiura and to compare treatment
outcomes with standard monotherapies.
PATIENTS AND METHODS
Study area and population. The study was conducted in Un-
guja, Zanzibar Island, Tanzania, from March through May
2009. Stool samples were collected from children attending
schools in Kinyasini and Kilombero, where soil-transmitted
helminthiasis is highly endemic [12]. Both schools are located
in district North A, 30–40 km northeast of Zanzibar Town.
Ethical considerations. Ethical approval was granted by the
Ethics Committee of Basel, Switzerland (13/09), and the Min-
istry of Health and Social Welfare, Zanzibar (ZAMEC/0001/
09). The trial was registered with Current Controlled Trials
(ISRCTN08336605). Written informed consent was obtained
from parents or guardians of participating children, whereas
children consented orally. Participation was voluntary, and in-
dividuals could withdraw from the trial at any time.
Eligibility criteria. Children attending grades 1–7 in the 2
schools were eligible if they met all of the following inclusion
criteria: written informed consent provided by parents or guard-
ians, age of 5 years or older, sufficiently large stool sample to
perform duplicate Kato-Katz thick smears at baseline survey,
infection with T. trichiura, and submission of second stool sample
subjected to duplicate Kato-Katz thick smears before treatment.
After randomization, children were excluded from treatment
if fulfilling any of the following exclusion criteria: pregnant (for
females), as verbally assessed by medical personnel; presence of
systemic illnesses (eg, fever or severe illness); and anthelmintic
treatment within the previous 4 weeks.
Sample size. Sample size calculation was based on the range
of CRs of albendazole and mebendazole (20%–45%) versus al-
bendazole plus ivermectin (65%–80%) against T. trichiura ac-
cording to recent reviews [6, 11]. Using a significance level of
.05 to detect greater efficacy of combination therapy, a power of
80%, and an equation by Fleiss [14], the minimum required
number of individuals per treatment group at different CRs was
105.
The prevalence of T. trichiura infections was conservatively
estimated to be 30% [12], and the compliance for stool sub-
mission was assumed to be 90% per sample. Hence, we estimated
that ∼2000 subjects were needed to identify 600 T. trichiura–
infected individuals. However, the baseline survey revealed a
prevalence of T. trichiura of 150% in both schools. Hence, we
stopped enrolling after 1240 children had been invited.
Baseline parasitologic survey. First, the name, age, sex, and
school grade of each child were recorded. Second, children
received containers with unique identification numbers and
were invited to bring a fresh stool sample the following morn-
ing. Within 2 weeks a total of 1240 children were invited to
participate. Children with a microscopically confirmed T. tri-
chiura infection were asked for a second stool sample, and their
body weight was recorded.
Randomization. The trial statistician was provided with the
list of identification numbers of 618 T. trichiura–positive chil-
dren and generated a computer-based random allocation se-
quence (numbers 1–4). The numbers were decoded for each
school by 1 of 2 researchers (S.K. for Kilombero and B.S. for
Kinyasini) to assign children either to albendazole (400 mg;
Laboratoria Wolfs) plus placebo (Hermes Edulcorants), alben-
dazole plus ivermectin (200 mg/kg; Merck), mebendazole (500
mg; Janssen-Cilag) plus placebo, or mebendazole plus iver-
mectin. Trial medications were prepared in identical envelopes
labeled with unique identification numbers and sealed. Because
ivermectin is administered according to patient weight, iver-
mectin and placebo tablets were counted and packed accord-
ing to children’s weight.
On the day of treatment, eligible children were examined by
medical personnel for exclusion criteria before drug adminis-
tration. Administrators opening the sealed envelopes and ad-
ministering the drugs were masked to group assignment. How-
ever, to the trained eye, the gravure on the albendazole or me-
bendazole tablets was not identical, and placebos were slightly
smaller than ivermectin tablets. Children could not see the tablets
because drug administrators placed the tablets directly in their
mouth, but differences in palatability and taste of the tablets
might exist. Drugs were swallowed with clean water and accom-
panied by a small food item. A clinician was present, monitored
acute adverse events (AEs), and provided medical assistance if
necessary. The staff of the nearby health centers had undergone
pharmacovigilance training. The medical staff was informed
about the date of treatment, and the health centers were provided
with first aid drugs (oral and intravenous analgesics and antian-
aphylactics) and remained open for 24 h after treatment. Chil-
dren, parents, and teachers were advised to refer to these health
centers in case of AEs.
All laboratory personnel, including the outcome assessors,
were masked to group assignment. Only the data examiners
saw unmasked data, and 1 of them (J.H.) had no contact with
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Figure 1. Flow diagram of the randomized controlled trial comparing the efficacy and safety of albendazole and mebendazole alone and in combination
with ivermectin against Trichuris trichiura in children from primary schools in Kinyasini and Kilombero on Unguja Island, Zanzibar, in early 2009.
the study participants, although the success of the masking was
not assessed formally.
Assessment of AEs. At 48 h after treatment, AEs due to the
treatment were assessed by a pretested questionnaire. Children
were interviewed by trained personnel of the Helminth Control
Laboratory Unguja (HCLU), who were familiar with potential
AEs resulting from anthelmintic treatment. Solicited AEs were
headache, vertigo, allergic reactions (pruritus, urticaria, and
anaphylaxis), shivering, abdominal cramps, nausea, vomiting,
diarrhea, and fever. The AEs were recorded and graded as fol-
lows: mild, indicating present but not requiring any interven-
tion; moderate, requiring medication for symptomatic relief on
request or present and interfering with normal daily activities;
and severe, requiring medical intervention beyond symptomat-
ic relief.
Follow-up. Three weeks after treatment, study participants
were asked for 2 consecutive stool samples. Approximately 120
children were enrolled daily, and the procedure was continued
for 3 weeks until, in the middle of May 2009, most treated
children had provided 2 stool samples for follow-up.
Laboratory procedures. Stool samples were transferred to
the HCLU and processed the same day, in accordance with
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Table 1. Baseline Demographic and Clinical Characteristics of 610 Children in a Randomized Controlled Trial in Early 2009 in the
Primary Schools of Kilombero and Kinyasini on Unguja Island, Zanzibar, Tanzania
Characteristic
Albendazole
plus placebo
(n p 150)
Albendazole
plus ivermectin
(n p 153)
Mebendazole
plus placebo
(n p 153)
Mebendazole
plus ivermectin
(n p 154)
Age, mean  SD, years 10.9  2.6 11.0  2.8 10.8  2.8
(152 observationsa)
11.0  2.6
No. of females/no. of males 71/79 84/69 89/64 92/62
No. of participants at Kilombero/at Kinyasini 52/98 53/100 54/99 54/100
Weight, mean  SD, kg 30.5  9.9
(145 observationsa)
30.6  10.2
(151 observationsa)
29.5  9.2
(149 observationsa)
29.4  8.9
(151 observationsa)
Infected with Trichuris trichiura
No. (%) of participants 150 (100) 153 (100) 153 (100) 154 (100)
EPG
Geometric mean 154 121 136 154
Median (range) 156 (66–302) 108 (54–276) 126 (60–282) 159 (78–273)
Infection intensity,b no. (%) of participants
Light 138 (92.0) 142 (92.8) 144 (94.1) 144 (93.5)
Moderate 12 (8.0) 11 (7.2) 9 (5.9) 10 (6.5)
Infected with Ascaris lumbricoides
No. (%) of participants 19 (12.7) 15 (9.8) 19 (12.4) 20 (13.0)
EPG
Geometric mean 3401 1839 2601 381
Median (range) 4584 (1122–17,772) 2904 (774–6846) 11394 (1104–23,394) 603 (17–8183)
Infection intensity, no. (%) of participants
Light 11 (57.9) 10 (66.7) 8 (42.1) 14 (70.0)
Moderate 7 (36.8) 4 (26.7) 11 (57.9) 5 (25.0)
Heavy 1 (5.3) 1 (6.6) 0 1 (5.0)
Infected with hookworm
No. (%) of participants 44 (29.3) 37 (24.2) 39 (25.5) 40 (26.0)
EPG
Geometric mean 60 66 65 64
Median (range) 60 (18–152) 66 (36–132) 48 (18–192) 51 (18–263)
Infection intensity,b no. (%) of participants
Light 44 (100) 36 (97.3) 39 (100) 40 (100)
Moderate 0 (0) 1 (2.7) 0 (0) 0 (0)
NOTE. EPG, eggs per gram of stool.
a Data were recorded only for the indicated number of children.
b None had heavy intensity.
standardized, quality-controlled methods [15]. Duplicate 41.7-
mg Kato-Katz thick smears were prepared [16]. Slides were
quantitatively examined under a microscope for the presence
of hookworm eggs after a clearing time of 20–40 min and for
T. trichiura and A. lumbricoides eggs a few hours later.
Primary and secondary outcomes. Primary outcome mea-
sures were the CR and egg reduction rate (ERR) achieved by
treatment with any drug regimen against T. trichiura infections.
Secondary outcome measures were the frequencies of AEs. The
CR was determined as the percentage of children excreting eggs
before treatment who became negative after treatment. The
ERR was calculated as the reduction in the group’s geometric
mean (GM) egg count, including infected and noninfected sub-
jects at follow-up, according to World Health Organization
(WHO) guidelines [17]. Confidence intervals (CIs) for the ERR
were calculated using a bootstrap resampling method with 2000
replicates.
Statistical analysis. An intention-to-treat analysis was pur-
sued. All individuals with primary end point data records were
included in the final analyses (Figure 1). The species-specific
numbers of helminth eggs recorded from 4 Kato-Katz slides
before and after treatment were added and multiplied by a
factor of 6 to obtain the arithmetic mean of the eggs per gram
of stool (EPG) for each individual. The arithmetic means were
used to determine whether the intensity of infection with soil-
transmitted helminths was light, moderate, or heavy, using
WHO cutoffs, and to calculate the GM infection intensities as
a summary measure among the treatment groups [17].
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Table 2. Cure Rates (CRs) and Egg Reduction Rates (ERRs) of Trichuris trichiura and Infection Characteristics of Ascaris lum-
bricoides and Hookworm after Administration of Albendazole and Mebendazole Given Alone or in Combination with Ivermectin
in a Tanzanian Study (n p 548)
Characteristic
Albendazole
plus placebo
Albendazole
plus ivermectin
Mebendazole
plus placebo
Mebendazole
plus ivermectin
Trichuris trichiura
No. of participants positive before treatment 132 140 138 138
No. (%) of participants still positive after treatment 119 (90.2) 87 (62.1) 112 (81.2) 62 (44.9)
CR, % (95% CI) 9.8 (5.4–16.3) 37.9 (29.8–46.4) 18.8 (12.7–26.4) 55.1 (46.4–63.5)
Geometric mean EPG
Before treatment 154 127 146 160
After treatment 92 11 49 5
ERR, % (95% CI)a 40.3 (21.5–55.7) 91.1 (87.2–94.0) 66.7 (52.3–76.9) 96.7 (95.0–97.9)
Hookworm
No. of participants positive before treatment 39 30 34 35
No. (%) of participants still positive after treatment 16 (41.0) 10 (33.3) 22 (64.7) 26 (74.3)
Geometric mean EPG
Before treatment 67 74 61 58
After treatment 4 3 13 29
Ascaris lumbricoides
No. of participants positive before treatment 14 14 18 18
No. (%) of participants still positive after treatment 0 (0) 1 (7.1) 4 (22.2) 0 (0)
Geometric mean EPG
Before treatment 2680 1699 2414 553
After treatment 0 1 5 0
NOTE. CI, confidence interval; EPG, eggs per gram of stool.
a The CIs of the ERRs were constructed by a bootstrap resampling.
The 2  2 factorial design enabled the determination of the
treatment efficacy of the 4 regimens against T. trichiura, the
determination of potential interactions between the interven-
tions, and the determination of the treatment efficacy of the
interventions by school, using regression analysis. Odds ra-
tios (ORs) and respective P values were used to explain differ-
ences among the 4 treatment groups. Significance was given at
.P ! .05
Differences in the median time (days) from treatment to the
last collected stool sample at follow-up between the schools
and the 4 treatment groups were assessed using the Wilcoxon
test. Drug-related AEs were analyzed using ordinal logistic re-
gression with the untoward effect classified as absent, mild,
moderate, or severe and the factorial treatment regimens (with-
out interaction term) as predictor variables.
Data were double-entered and discrepancies were removed
in tracing back to original records. Statistical analyses were
performed using Stata software, version 10 (StataCorp); boot-
strap CIs were calculated using R 2.9.1 (R Development Core
Team).
RESULTS
Study cohort. Among 1240 children invited for the baseline
screening, 174 did not participate, and 456 were excluded (Fig-
ure 1). The remaining 610 children were randomly assigned
to 1 of the 4 treatment arms. An additional 8 children were
wrongly included in the randomization, although they were not
infected with T. trichiura ( ) or had incomplete parasi-np 2
tological data ( ). These children were excluded from sub-np 6
sequent analyses. Thirty-eight children did not receive the as-
signed intervention because they either were absent during the
treatment ( ) or met 1 of the exclusion criteria at thenp 36
day of treatment ( ). Twenty-four children were lost tonp 2
follow-up. Complete data records for the final analysis were
available for 548 children. AEs were determined from 564
(99%) of the 572 treated children.
Baseline parasitologic survey. Overall, 1066 children sub-
mitted a stool sample for Kato-Katz examination at baseline.
The prevalence of T. trichiura was 63%. Hookworm and A.
lumbricoides infections were diagnosed in 20% and 9% of the
children, respectively.
Baseline characteristics. The mean age of the 610 random-
ized children was 11 years (Table 1). Children’s mean weight
was similar in all groups (range, 29.4–30.6 kg). The proportion
of girls differed slightly among groups (range, 47%–60%). The
GMs of T. trichiura infections were similar in the 4 treatment
groups (121–154 EPG), and infection intensities were mainly
light (92%–94%).
Albendazole, Mebendazole, and Ivermectin • CID 2010:51 (15 December) • 1425
Table 3. Multiple Regression Analysis for the 2  2 Factorial Design to Assess the Risk
of a Persistent Trichuris trichiura Infection after Treatment in 548 Schoolchildren from
Kilombero and Kinyasini in Tanzania
Type of analysis OR (95% CI) P
Primary analysis (n p 548)
Albendazole (vs mebendazole) 2.05 (1.38–3.04) !.001
Placebo (vs ivermectin) 5.40 (3.55–8.22) !.001
Kinyasini (vs Kilombero) 1.08 (0.72–1.63) .702
2-way analysis (n p 548)
Albendazole (vs mebendazole) 1.47 (0.72–2.99) .285
Placebo (vs ivermectin) 8.54 (3.73–19.59) !.001
Kinyasini (vs Kilombero) 1.08 (0.57–2.07) .806
Ivermectin  mebendazole (vs ivermectin  albendazole) 1.03 (0.43–2.44) .950
Albendazole  Kinyasini (vs albendazole  Kilombero) 1.66 (0.72–3.83) .236
Ivermectin  Kinyasini (vs ivermectin  Kilombero) 0.49 (0.20–1.20) .118
Adjusted analysis (n p 548)
Albendazole (vs mebendazole) 2.02 (1.35–3.00) .001
Placebo (vs ivermectin) 5.40 (3.54–8.25) !.001
Kinyasini (vs Kilombero) 0.98 (0.54–1.78) .951
Female sex (vs male sex) 0.68 (0.45–1.02) .059
Age 0.97 (0.90–1.05) .407
Days from treatment to last follow-up stool sample 1.01 (0.96–1.07) .642
NOTE. Two-way interactions between the effects of the medications (interaction term: ivermectin 
albendazole, ivermectin  mebendazole) and between the effects of schools and medications (interaction
term: ivermectin Kinyasini, albendazole Kinyasini) were assessed. The outcome variable was a T. trichiura
infection after treatment. Explanatory variables in parentheses (“vs variable”) indicate the baseline of com-
parison. CI, confidence interval; OR, odds ratio.
The proportion of children coinfected with hookworm
(range, 24%–29%) and the intensity of hookworm infection
(range, 60–66 EPG) were similar in all groups. Concurrent
infections with A. lumbricoides were found in 10%–13%; the
GM was highest in the albendazole-placebo group (3401 EPG)
and lowest in the mebendazole-ivermectin group (381 EPG).
Time difference for follow-up. Stool samples for follow-up
were collected 22–39 days after treatment. The median follow-
up period was 23 days in Kilombero and 30 days in Kinyasini
( ). The median follow-up period for the 4 treatmentP ! .001
groups was 29 days for all groups ( ).Pp .954
CR and ERR against T. trichiura. By design, all children
included in the primary analysis were infected with T. trichiura
before treatment. The highest CR (55%) was achieved with a
mebendazole-ivermectin combination, followed by albenda-
zole-ivermectin (38%). Particularly low CRs were achieved
when administering albendazole and mebendazole alone (10%
and 19%, respectively) (Table 2).
Because there was no evidence of a statistically significant
interaction between the effects of the medications (OR, 1.03;
95% CI, 0.43–2.44; Table 3), the effect of each drug on T.
trichiura can be interpreted individually according to the results
of the primary analysis. Mebendazole cured statistically signif-
icantly more T. trichiura than albendazole (OR, 2.05; 95% CI,
1.38–3.04), and ivermectin cured significantly more T. trichiura
than placebo (OR, 5.40; 95% CI, 3.55–8.22). Hence, ivermectin
has an additive effect on both albendazole and mebendazole.
After adjusting for sex, age, and days to last follow-up stool
sample, none of the estimates changed significantly. The ad-
dition of ivermectin to albendazole or mebendazole improved
the CR from 14% to 47%, compared with placebo (Figure 2).
Mebendazole, regardless of whether combined with ivermectin
or placebo, showed a higher CR than the albendazole analogous
treatments (37% vs 24%).
The pattern observed for ERRs was similar to that for CRs
(Table 2). Medication with mebendazole-ivermectin resulted in
the highest ERR (97%; bootstrap 95% CI, 95%–98%). Treat-
ment with albendazole-ivermectin resulted in a statistically sig-
nificant lower ERR (91%; 95% CI, 87%–94%), as indicated by
nonoverlapping bootstrap CIs. Lowest ERRs were achieved
when applying mebendazole (67%; 95% CI, 52%–77%) or al-
bendazole (40%; 95% CI, 22%–56%) alone.
Treatment outcome on hookworm and A. lumbricoides.
Concurrent hookworm and A. lumbricoides infections were
found in 25% and 12%, respectively, of the 548 children in-
cluded in the primary analysis. The highest decreases in prev-
alence and intensity of hookworm infections were found within
the albendazole-treated groups (Table 2). No drug combination
was superior to albendazole treatment against A. lumbricoides.
AEs. Abdominal cramps were reported by 13% (72 of 564)
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Figure 2. Independent treatment effects of albendazole versus me-
bendazole and of ivermectin versus placebo on infection intensities of
Trichuris trichiura (administration of albendazole and mebendazole alone
and in combination with ivermectin in a 2  2 factorial design). Infection
intensities were classified according to World Health Organization cut-
offs [17]. Intensity class no represents the cure rate; light, light infection
intensities after treatment; moderate, moderate infection intensities after
treatment, and heavy, heavy infection intensities after treatment.
Table 4. Adverse Events (AEs) Reported 48 Hours after Treatment with Albendazole or Mebendazole in Combination
with Ivermectin or Placebo by Schoolchildren from Kinyasini and Kilombero on Unguja Island, Zanzibar (n p 564)
Characteristic
Albendazole
plus placebo
(n p 136)
Albendazole
plus ivermectin
(n p 144)
Mebendazole
plus placebo
(n p 143)
Mebendazole
plus ivermectin
(n p 141)
AEs
AEs of
moderate
intensity AEs
AEs of
moderate
intensity AEs
AEs of
moderate
intensity AE
AEs of
moderate
intensity
Abdominal cramps 15 (11.0) 3 21 (14.6) 12 17 (11.9) 3 19 (13.5) 6
Fatigue 8 (5.9) NA 4 (2.8) NA 6 (4.2) NA 9 (6.4) NA
Headache 8 (5.9) 5 5 (3.5) 3 7 (4.9) 1 7 (5.0) 2
Nausea 5 (3.7) 1 11 (7.6) 4 3 (2.1) 2 7 (5.0) 0
Diarrhea 6 (4.4) 0 4 (2.8) 2 5 (3.5) 1 4 (2.8) 0
Vertigo 6 (4.4) 2 2 (1.7) 2 6 (4.2) 1 5 (3.5) 0
Fever 4 (2.9) 1 6 (4.2) 3 4 (2.8) 2 2 (1.4) 0
Vomiting 3 (2.2) 0 3 (2.1) 1 3 (2.1) 0 0 (0) 0
Allergic reaction 2 (1.7)a 0 5 (3.5)a, b 3 1 (0.7)b 1 0 (0) 0
Shivering 3 (2.2) 0 3 (2.1) 2 0 (0) 0 0 (0) 0
Total 60 12 64 32 52 11 53 8
Note. Data are no. or no. (%) of children who experienced AEs. NA, not applicable.
a Pruritus without rash.
b Localized urticaria.
of the participants, headache and fatigue by 5% (27 of 564),
nausea by 5% (26 of 564), diarrhea and vertigo by 3% (19 of
564), and allergic reactions by 1.4% (8 of 564) (Table 4). Four
children reported pruritus without rash, 4 had localized urti-
caria, and 6 reported shivering. Most AEs (72%; 166 of 229)
were mild, the remaining 28% (63 of 229) were moderate. AEs
were mainly self limiting. Relief through drugs was sought by
29 children, and 3 used local remedies.
The proportion and intensity of abdominal cramps were
slightly higher in the treatment regimens containing ivermectin,
without statistical significance (OR, 1.30; 95% CI, 0.79–2.14)
(Table 4). Girls reported vertigo statistically significantly less
often than boys (OR, 0.22; 95% CI, 0.06–0.76). Older children
were more likely to experience fatigue (OR, 1.53; 95% CI, 1.04–
2.26) but reported less vomiting (OR, 0.71; 95% CI, 0.53–0.95)
and diarrhea (OR, 0.81; 95% CI, 0.67–0.98). Children with
moderate T. trichiura infection intensities at baseline were more
likely to report shivering than those with light infections (OR,
6.76; 95% CI, 1.20–38.11).
DISCUSSION
We found low CRs with standard single-dose albendazole and
mebendazole against T. trichiura infections among schoolchil-
dren in Zanzibar, confirming results from a meta-analysis of
randomized, placebo-controlled trials [6]. An albendazole-iver-
mectin combination resulted in a statistically significant higher
CR against T. trichiura, hence supporting findings from 2 pre-
vious trials [8, 9]. A mebendazole-ivermectin combination—
used for the first time against T. trichiura—resulted in statis-
tically higher CRs and ERRs than any of the other treatments.
High ERRs are particularly relevant for morbidity control.
Our results confirm previous findings reviewed by Olsen [11]
(ie, elevated efficacy against T. trichiura when albendazole was
combined with ivermectin) but contrast to findings from a
Ugandan trial in which concurrent administration of ivermec-
tin failed to enhance efficacy in curing T. trichiura infections
in pregnant women [10]. However, in the Ugandan study, only
17 individuals were infected with T. trichiura; hence, results
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have to be interpreted with caution. Compared with other trials,
our trial found considerably lower CRs and ERRs with alben-
dazole and mebendazole alone and an albendazole-ivermectin
combination against T. trichiura [6, 10, 11]. A plausible expla-
nation is that we used a more rigorous diagnostic approach
with 4 Kato-Katz thick smears examined before and after treat-
ment. Indeed, CRs would have been considerably higher if only
duplicate Kato-Katz thick smears were examined before and
after treatment: 60% for mebendazole-ivermectin, 53% for al-
bendazole-ivermectin, 30% for mebendazole, and 21% for al-
bendazole. A potential onset of drug resistance should be kept
in mind, not least because of high anthelmintic drug pressure
in Zanzibar during the past 15 years [12, 18, 19]. The low
efficacy of albendazole against T. trichiura in our study is wor-
rying also, because a prior spot-check had revealed a low CR
of 25% in preschool-aged children, using a less rigorous di-
agnostic approach [18]. Although a trial conducted on the
neighboring island Pemba in 1992–1993 had revealed similarly
low CRs of albendazole and mebendazole against T. trichiura
as found in our study, the ERR of albendazole against T. tri-
chiura had been significantly higher (73%) [20]. An ERR !50%
raises concern and should trigger more detailed investigations
(eg, in vitro tests for further clarification of whether resistance
is emerging), as has been previously suggested for schistoso-
miasis [21]. With the exception of the egg hatch assay for
human hookworm [22, 23], in vitro tests for the biological
confirmation of anthelmintic resistance have yet to be devel-
oped for human nematode infections.
Compared with CRs of other treatment options against T.
trichiura (eg, combination therapies with pyrantel-oxantel [CR,
32%] [24] or mebendazole-levamisole [CR, 23%] or treatment
with levamisole [CR, 10%] [19] or tribendimdine alone [CR,
0] [25]), the CRs observed in our study for the 2 ivermectin
combined therapies were considerably higher.
The small groups for assessment of treatment outcomes of
the 4 treatment regimens against hookworm and A. lumbri-
coides resulting from low prevalences of coinfections are a lim-
itation of our study. The highest decrease in both prevalence
and infection intensity was achieved with albendazole, regard-
less of whether it was combined with ivermectin, in line with
previous findings [6, 26].
Regarding the helminth reinfection potential in Zanzibar, the
follow-up period of 3–5 weeks after treatment might be con-
sidered another limitation of our study. Anthelmintic drug ef-
ficacy should be monitored 2–3 weeks after treatment [27]. How-
ever, an increase in time until the last follow-up stool sample
after treatment was collected showed no association with T. tri-
chiura infection in our study. Hence, potential reinfections should
not have confounded our results.
The different treatments investigated here were safe, and AEs
were transient and mostly mild. Nevertheless, compared with
a previous review in which only gastrointestinal AEs occurred
with a frequency of 11% [28], not only did we observe ab-
dominal cramps and diarrhea, but also most other solicited
AEs showed frequencies 11%. However, the frequency of AEs
in our study may be overestimated because we did not assess
pretreatment conditions, which may allow distinguishing be-
tween treatment-related and treatment-unrelated AEs. Impor-
tantly, the prevalence and intensity of soil-transmitted helminth
infections in Zanzibar have significantly decreased during the
past 15 years [12]. Because there might be higher rates of AEs
in populations with higher infection rates and no previous
treatment history, similar studies are needed to ensure like-for-
like comparisons.
In conclusion, the addition of ivermectin to albendazole and
mebendazole improves treatment outcomes against T. trichiura
and will have an extra beneficial effect against an often coen-
demic but neglected soil-transmitted helminth, Strongyloides
stercoralis, and against coendemic ectoparasites. These drug
combinations may be considered in soil-transmitted helminth
control programs and individual patient management.
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